stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) Shares outstanding
Maravai LifeSciences Holdings, Inc.'s shares outstanding at the end of fiscal 2025 was $144.4M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $149.1M. Over the past ten years it has ranged from $28.9M (fiscal 2020) to $257.8M (fiscal 2021); the current reading is higher than 50% of that period. Maravai LifeSciences Holdings, Inc. ranks 81st of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $144.4M | 4.68% |
| FY2024 | $137.9M | 4.54% |
| FY2023 | $131.9M | (48.33%) |
| FY2022 | $255.3M | (0.96%) |
| FY2021 | $257.8M | 791.81% |
| FY2020 | $28.9M | (88.62%) |
| FY2019 | $253.9M | 0.00% |
| FY2018 | $253.9M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $149.1M | 0.72% |
| Jun 2026 | $148.0M | 1.07% |
| Mar 2026 | $146.4M | 1.43% |
| Dec 2025 | $144.4M | (0.22%) |
| 24 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| VIR Vir Biotechnology, Inc. compare | $169.3M |
| TRVI Trevi Therapeutics, Inc. compare | $156.6M |
| MRVI Maravai LifeSciences Holdings, Inc. | $149.1M |
| SRPT Sarepta Therapeutics, Inc. compare | $105.9M |
| REPL Replimune Group, Inc. compare | $105.2M |
| MESO Mesoblast Limited compare | $77.8M |
| HRMY Harmony Biosciences Holdings, Inc. compare | $59.7M |
| MAZE Maze Therapeutics, Inc. compare | $59.0M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $35.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item